Betrixaban is an anticoagulant medication used to prevent blood clots from forming in people who are at risk of developing a blood clot in the veins of their legs (deep vein thrombosis) or lungs (pulmonary embolism). It works by inhibiting the action of certain clotting factors in the blood that can lead to clot formation. Betrixaban is a relatively new anticoagulant, approved by the FDA in 2016. It is usually taken orally once a day and may be used in combination with antiplatelet medications such as aspirin. It is used primarily in people who are at risk of developing a blood clot due to certain medical conditions, such as atrial fibrillation, heart valve replacement surgery, or recent major surgery.
Betrixaban, sold under the brand name Bevyxxa, is a medication used to prevent blood clots in adults hospitalized for an acute medical illness who are at high risk for developing blood clots in the legs (deep vein thrombosis) or lungs (pulmonary embolism).
Here's a breakdown of its key aspects:
Type of drug: Anticoagulant, specifically a direct factor Xa inhibitor. This means it directly blocks a specific clotting factor (factor Xa) in the blood clotting cascade, preventing the formation of blood clots.
Function: Reduces the risk of blood clots in high-risk hospitalized patients.
Administration: Taken orally (by mouth) as a tablet.
Benefits: Compared to other similar medications, betrixaban has relatively low excretion through the kidneys and is not metabolized by a specific liver enzyme (CYP3A4), which can be helpful for patients with impaired kidney or liver function.